Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00004029 · ClinicalTrials.gov registry record · Phase 1
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
NCT00004029: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00004029 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 46 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00004029, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
Study Summary
Phase I trial to study the effectiveness of vaccine therapy in treating patients with metastatic prostate cancer. Vaccines may make the body build an immune response to kill tumor cells.
Interventions
- BIOLOGICAL sargramostim
- BIOLOGICAL recombinant viral vaccine therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 1996-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00004029
The ClinicalTrials.gov registry entry for NCT00004029 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which sargramostim is the first listed.
NCT00004029 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00004029 about?
NCT00004029 is a clinical study titled "Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer". Phase I trial to study the effectiveness of vaccine therapy in treating patients with metastatic prostate cancer. Vaccines may make the body build an immune response to kill tumor cells.
What is the current status of trial NCT00004029?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 1996-12.
What interventions are being tested in trial NCT00004029?
The interventions under investigation include: sargramostim (BIOLOGICAL), recombinant viral vaccine therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00004029?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.